CUTISS AG

🚀 Clinical trials update from CUTISS! We’re excited to announce a positive interim analysis on the efficacy of our lead product denovoSkin™ (versus standard of care) from the Phase 2 clinical trial in reconstructive skin surgery. This trial focuses on pediatric, adolescent and adult patients requiring skin grafts in skin reconstructive procedures. denovoSkin™ aims to provide a solution to reduce scarring and therefore improve healing outcomes. “These results confirm our mission to provide access to denovoSkin™ beyond burns, changing the status quo in skin surgery globally,” said Daniela Marino, CEO of CUTISS. “We extend our heartfelt gratitude to all involved in this multicentric trial across Switzerland, Italy, and the Netherlands.” The full data analysis with one-year follow-up results is expected in early 2025. Read our press release for more details: https://lnkd.in/ektSC2ij #RegenerativeMedicine #Innovation #Healthcare #ClinicalTrials #SkinSurgery

We were delighted to participate in the 20th SECA Conference, titled "Value Creation through Innovation”. It’s one of the largest conferences in Switzerland bringing together the private equity, venture capital and corporate finance industry.   Our CEO Daniela Marino participated in the Healthcare Value Creation panel with Chandra P. Leo, Richard Fritschi and Guido Kamann, highlighting our pioneering work in regenerative medicine and its transformative global impact on healthcare.   Thank you to Javier Rivas, FIA CFA for moderating and thanks John Cook, Maurice R.H. Pedergnana and SECA for hosting this enriching conference and to everyone who engaged with us! SECA - Swiss Private Equity & Corporate Finance Association #regenerativemedicine #seca #privateequity #fundraising #innovation #healthcare

🚀 Exciting News from CUTISS! 🚀 We're delighted to announce the first closing of CHF 25 million in our Series C funding round! This funding supports the continued development and path to commercialization of our skin cell therapies denovoSkin™ and Viticell®. A huge thank you to the new US-based co-lead investor and the other Swiss and international investors. This milestone allows us to advance to Phase 3 clinical trials and move closer to bringing our life-changing therapies to patients.   We invite additional investors to join us on our mission to transform skin surgery and improve patient outcomes worldwide. For more details, read our press release: https://lnkd.in/eUVecez2 #RegenerativeMedicine #Biotech #Innovation #FundingNews #SeriesC

A significant milestone in pediatric burn care in Italy – the inauguration of the new pediatric burn center at Santobono Hospital in Naples, a new center of excellence at European level!    Since 2021, Santobono has been the coordinating center in Italy for our Phase 2 clinical trial of denovoSkin™, CUTISS’ bioengineered autologous human skin tissue. Notably, Santobono was the first pediatric center in the world to perform a denovoSkin™ transplant in a neonate.   We feel incredibly proud and honored to collaborate on this groundbreaking project with Marcello Zamparelli, underscoring our commitment to change the status quo in skin surgery and improve patient outcomes with cutting-edge regenerative medicine.    The new facility will enable quicker interventions for patients and allow continuous control, monitoring, and verification of the therapies and innovative treatments they receive.   Burns are the 3rd leading cause of death in children. In Campania region of Italy, between 2022 and 2023, 120 young patients were treated. Of these, 70% had severe or very severe burns; 80% required surgical hospitalizations. It is in this context that the new pediatric burn center at Santobono-Pausilipon was inaugurated yesterday.   Watch snippets of the La Presse reportage below and for more details read on here:  Rai - Radiotelevisione Italiana: https://lnkd.in/eu9RTWck LaPresse SpA: https://lnkd.in/e443sPTH ANSA news agency: https://lnkd.in/e_VXv4Mu Il Mattino: https://lnkd.in/eEVRHhWX    #PediatricCare #RegenerativeMedicine #Innovation #BurnTreatment Regione Campania Comune di Napoli Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon

We’re driven to change the status quo in skin surgery.   At the Swiss Biotech Day this week, we were among the selected companies in the clinical stage category invited to present. Our CEO Daniela Marino took the stage to share CUTISS’s recent milestones and our next last-stage clinical steps, and to illustrate our approach to revolutionize skin surgery.   Let’s keep pushing the boundaries of what's possible in regenerative medicine!   #SwissBiotechDay #RegenerativeMedicine #Biotech #Innovation #BioEngineering

We’re thrilled to be at Swiss Biotech Day on Tuesday 23 April, in Basel. Our CEO Dr Daniela Marino will be attending to pitch to investors, and showcase our latest developments in skin regenerative medicine. If you want to learn and find out more about what’s coming up for CUTISS, reach out to schedule a meeting!   #SwissBiotechDay #regenerativemedicine #skin #innovation #biotech

In 2021, the total incident population of burn injuries across the 7MM was approximately 2 million, with the US accounting for 662,000 cases. Additionally, the Burns market is projected to experience substantial growth with a significant CAGR by 2032. CUTISS AG is leading the scene with personalized tissue engineering to address the unmet needs in burns and beyond. #treatmentforburns #regenerativemedicine #automation

🎉 7 years ago, on this very day, we embarked on an ambitious mission to push the boundaries of innovation in regenerative medicine.   Throughout these years, CUTISS achieved remarkable milestones, edging ever closer to the breakthrough of developing the first personalized skin tissue therapy.   We stay motivated by our dedicated team, supported by our fantastic investors and partners, and inspired every day by the patients participating in our clinical trials.   The upcoming phases of development and growth promise to be even more exciting… Here we 🚀#gogogo !

📣We’re excited to announce the one-year follow-up data from the Phase 2 clinical trial of denovoSkin™ in adult and adolescent severe burn patients.    The data shows that denovoSkin™, our personalized, bilayer bioengineered skin graft, can safely cover severe burn wounds, significantly sparing patients’ healthy donor sites while improving overall scar quality when compared to standard of care.   This trial update is incredibly important and marks a key advancement in the treatment for severe burns!   We thank the team of researchers and clinicians for their continued dedication and hard work, and the patients and their families for their courage.   As this Phase 2 trial continues towards its three-year follow-up mark, CUTISS is also taking steps towards regulatory approval. Our goal is to make denovoSkin™ broadly available to patients worldwide, addressing the urgent need for better burn treatment solutions.   👉 You can read our press release here: https://lnkd.in/erq68Mvk   #clinicaltrials #RegenerativeMedicine #Innovation #Healthtech #Biotech #Skin

Swiss television’s TeleZüri featured a compelling reportage on how our innovative treatment denovoSkin™ can make a difference for young burn patients like Julius. This coverage underscores our work and commitment to not only saving lives, but also improving the quality of life for patients suffering from severe burns. 👉 Watch the story: https://lnkd.in/etNtAHme #innovation #regenerativemedicine #skin #burns